Bater Kristin, Rieder Evan
J Drugs Dermatol. 2018 Dec 1;17(12):1317-1321.
Introduction: A limited number of treatments have been approved for androgenetic alopecia, however, myriad over-the-counter products for hair loss are available and readily purchased by consumers. This study aims to provide an overview of popular over-the-counter hair loss products and to review the available evidence regarding their use. Methods: Top-selling hair loss products were identified using sales data from the online retailer Amazon.com. The active ingredients, consumer ratings, quantity, and price were collected for each product. A search of the literature was conducted for ingredients that frequently appeared on the top-seller list. Results: Forty-two of the top 50 products met inclusion criteria, including orals (21.4%), topicals (35.7%), or shampoos/conditioners (42.9%). Common active ingredients included minoxidil, nutrients (ie, vitamins, minerals, proteins), and plant-based botanicals. 23.8% of products were FDA-approved treatments for androgenetic alopecia. Evidence for non-approved treatments is limited to small studies without generalizability. Discussion: While some over-the-counter treatments may be efficacious, more rigorous study is required. Dermatologists should be equipped to discuss the efficacy of these therapies as well as the risks and benefits associated with their use with patients. J Drugs Dermatol. 2018;17(12):1317-1321.
虽然已获批用于治疗雄激素性脱发的疗法数量有限，但市面上有大量非处方脱发产品可供消费者轻松购买。本研究旨在概述热门非处方脱发产品，并综述有关其使用的现有证据。方法：利用在线零售商亚马逊网站的销售数据确定最畅销的脱发产品。收集每种产品的活性成分、消费者评分、数量和价格。对畅销产品清单上频繁出现的成分进行文献检索。结果：前50种产品中有42种符合纳入标准，包括口服产品（21.4%）、局部用产品（35.7%）或洗发水/护发素（42.9%）。常见的活性成分包括米诺地尔、营养素（如维生素、矿物质、蛋白质）和植物性植物提取物。23.8%的产品是美国食品药品监督管理局（FDA）批准的雄激素性脱发治疗药物。未经批准的治疗方法的证据仅限于缺乏普遍性的小型研究。讨论：虽然一些非处方治疗可能有效，但仍需要更严格的研究。皮肤科医生应具备与患者讨论这些疗法的疗效以及使用它们的风险和益处的能力。《药物皮肤病学杂志》。2018年；17(12):1317 - 1321。
